Member Info for Badsterman

Morning Sea, trying to find the positives is difficult!

They use various excuses, including aggressive discounting from Echo Frames, Rayban etc.

Also: "manufacturing issues with the Lucyd safety glass product line caused this product launch to also be delayed, and is now planned to launch in the second quarter of 2024".

The delisting issue still concerns me. My view remains that they need a deal, partnership or contract to lift the SP.

Https://tinyurl.com/3j5tc8v7

Net loss of $1,551,105

Gross profit of $80,344.

Total value of glasses sold; a mere $221,875.

My initial thoughts are an awful set of results, I'm still wading through the detail. However, they still have close to $4 million in cash.

🫣

Should be titled "P3", sorry.

Imfinzi (durvalumab) failed to meet the primary endpoint of progression free survival in NSCLC.

Sad news for patients, however ;

"A pilot phase II clinical trial showed that VAL401 treatment has a statistically significant improvement in overall survival for patients with late stage non-small cell lung cancer."

https://link.springer.com/article/10.1007/s13318-018-00538-4

I really believe 2024 is going to be a pivotal year for Valirx, IF Suzy can get the funding.

Not long to find out......

Stingray Bio are targeting the LMTK3 kinase, there is a paper on this (from Jan 2023), co-authored by Georgios Giamas (one of Stingray Bio's founders and a director);

https://pubmed.ncbi.nlm.nih.gov/36614307/

In defence of the Board; they were stymied by the incompetent MHRA, for seven months.

If we'd have opted to trial in Oz, instead of the UK, we'd be close to p1 data by now.

Hindsight, eh?

Agree with that Top, particularly about getting a deal.

A major partner would seem the only escape route that Lucy have.

Or the sale of the company, perhaps to a major optical retailer.

I'll wait for the 10-Q...🙄

LUCY 10-Q must be due, last one was the 11th August.

The NASDAQ non-compliance notice was issued on the 4th August. They've 180 days from then for the price to be above $1, for 30 consecutive days.

Without better numbers they'll be dangerously close to delisting next year, before Reebok, Eddie Bauer and Nautica even come on stream.

If the quarterly revenue numbers are weak then Harrison Gross has to be replaced.

Fake news (again),

The EUDA website has been down since the weekend. 264 shares traded (on ii) and I can buy @$1.44.

You're all bonkers.

Do us a favour Gunner, sell up!

"A jolly"?

Do you want the directors to sit in a Pampisford office waiting for the Golden Goose to come knocking?

"Save their necks".

Do you think they sat about waiting for the MHRA? No, they took the bull by the horns and went to Oz.

I can read your broken record reply already....."12 years and nothing, moan, moan, moan"....ad infinitum.

Exactly fella,

I can't wait for "deal" or "no deal" day.

Hopefully we'll have clinical trials, evaluations and scientific partnerships to discuss - for a change!👍

Or maybe a placing...🫣

Good luck!!

Wayne,

We've not had news because I'd guess it all hinges on the cash for VAL201.

It'll be the catalyst for some big moves at Valirx.

Hang in there!!

👍

ADASTEC already run a 3.73 mile Level 4 route in Stavanger for an automated bus service.

I guess they need Guident for human intervention to help passengers with mobility issues.

That's how I read it.

Excellent news.

Nice find Mr Rozzy,

Can you provide a link? I'd be very interested to read about it.

ADASTEC provide automated bus tech (amongst other things).

👍

Source: taken directly from the Telegram group, posted by Harrison Gross;

"All as you know I have a limitations on what I can say and it must be public information. Here is a brief update for our community giving as much information as possible.

Software

We are making good progress on the apps front, as you may be aware we launched the first ever voice interface for ChatGPT in April, making our glasses the first with access to this powerful AI. The Lucyd app has been well received by users and provides free access to the paid version of ChatGPT. A massive 2.0 update just launched for iOS with additional AI tools and significant interface upgrades, the Android 2.0 version is coming in 2 weeks.

More features are planned for the Lucyd app and the tokenization plans for the Vyrb app are still underway. This has been delayed by a variety of factors related to the glasses and resource allotments, but is still underway and a committed part of our roadmap.

We have also hired a full time IOS engineer to support our CTO Eric and continue to build our software ecosystem more rapidly than before - we anticipate hiring a full time Android engineer as well in the near future. We also leverage several external developer teams to have some extra support in software development.

If you’ve downloaded Vyrb you’ve seen that we have put together a lot of really useful creator tools in one place - livestreaming audio, traditional social media elements, importing audio and light audio editing capabilities. More to come here as we aim to make Vyrb the ideal platform for free expression, control of your content and monetization of content.

Glasses

The new Lucyd Lyte XL frames launched last week, they are our most advanced glasses ever and I would be glad to get some out to our community here for some tokens. This product is clear evidence of our long-term commitment to revolutionizing smart eyewear and boasts our new patent-pending flexible hinges, thinnest temples yet and best sound quality yet by miles. These glasses are really a design achievement and are built on 5+ years of smartglass R&D.

Nautica powered by Lucyd, Eddie Bauer powered by Lucyd, and Reebok powered by Lucyd collections are all coming in the next six months and will likely raise the profile of our company significantly.

So in essence we are well on our way to realizing the mission of the Lucyd whitepaper: we are creating revolutionary smart eyewear products and a peer-to-peer content economy for smart eyewear, via the Vyrb app. So much infrastructure and technology has been developed towards this ultimate goal, and the vision remains the same: a future where people create, share and enjoy content on their glasses."

A very comprehensive offering, although you have to apply via an authorised third party to get Medicare or Medicaid.

They've got a chatbot with a $500 sale offer already!

I expect Lolly will be along shortly to dampen our enthusiasm. 😀

Indeed Sea,

Buy, lease or rent - prescription required. Plenty of add-ons to boost the profit such as accessories, warranties, finance and spare cartridges.

https://xploroxygen.com/product/discov-r/

Unfortunately no numbers of units sold, from the direct to consumer test.

We disagree Lolly,

In my view, it's wrong to suggest that TEK's "business model is broken".

BELL have a FDA authorised product, large contracts with McKesson and Innomax and HNWI investor backing.

I don't see that as failure, I see it as an investment opportunity.

I guess that's where we differ, glass half full and all that.

Good luck with your strategy. 👍

Gotta disagree chaps,

Cliff's a wily operator, he's been here before at sub 10p.

I guarantee he'll pull an RNS out of the bag to boost the SP, before any raise.

My guess would be AI related, given the recent developments in the Half Year report. Although, with five portfolio companies, there are plenty of opportunities for good news.

Indeed Veteran,

BELL merger is nearing completion, with funds to fulfil contracts and HNWI's backing the CLN's.

Lucy up 12.69% too.

Microsalt could be delayed for financial, technical or legal reasons.

I grabbed a couple of grands worth last night at 9p and 9.2p.

Be greedy when others are fearful, eh?